An oral synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain.
A synthetic cannabinoid, which mimics the main chemical compound of cannabis (THC).
Similar to the active ingredient found in naturally occurring Cannabis sativa L.
Marketed as Cesamet.
A schedule II agent.
It was approved for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics.
Approved for use in treatment of anorexia and weight loss in patients with AIDS.
Trials demonstrated benefits for conditions such as fibromyalgia and multiple sclerosis.
Nabilone is also effective in the treatment of inflammatory bowel disease.
The administration of nabilone reduces the frequency and/or intensity of nightmares in posttraumatic stress disorder in a significant number of patients.
Synthetic cannabinoid for treatment of nausea and vomiting with cancer chemotherapy in those who have failed conventional antiemetic treatment.
1-2 mg orally twice per day.
Adverse reactions include vertigo, drowsiness, dry mouth, ataxia, euphoria, sleep disturbance, dysphoria, headache, disorientation and depersonalization.
Aside from benefits for refractory chemotherapy induced nausea and vomiting, it improves pain and anxiety.
Optimizes pain and cluster symptom management in advanced cancer.